hat
FTSE 100 konpayi, ak konseye PR yo, pafwa di ke "kouri" yon gwo konpayi se yon tach gwo, ak nan tèt li jistifye yon salè gwo. Men, jan Sir Filip Hampton, yon figi biznis sezonman ak prezidan nan pharma jeyan nan GlaxoSmithKline, te di Peye Centre lan segondè ane sa a ki bigness pa nesesèman vle di CEO nan merite yon rekonpans gwo. "Pi gwo sistèm nan nan, plis la konte yo sistèm, olye ke moun nan nan tèt la nan li,"Li te di.
eng
FTSE 100 companies, and their PR advisers, sometimes say that “running” a big company is a huge task, and in itself justifies a big salary. But as Sir Philip Hampton, a seasoned business figure and chairman of the pharma giant GlaxoSmithKline, told the High Pay Centre this year that bigness does not necessarily imply the CEO deserves a huge reward. “The bigger the system, the more the system counts, rather than the person at the top of it,” he said.